SECONDARY ACUTE MYELOID LEUKEMIA
Clinical trials for SECONDARY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for SECONDARY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Matching AML therapy to genetics and fitness boosts survival in seniors
Disease control CompletedThis study looked at whether tailoring chemotherapy for older adults (60+) with acute myeloid leukemia (AML) based on their genetic profile and overall health can improve outcomes. 75 participants received either standard intensive or milder therapy based on these factors. The go…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
New drug combo shows promise in Tough-to-Treat leukemia
Disease control CompletedThis early-phase study tested two drugs, pevonedistat and decitabine, together in 12 people with high-risk acute myeloid leukemia (AML). The main goal was to find the safest dose and understand side effects. Researchers also looked at whether the combination could help control th…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:54 UTC
-
New hope for kids with tough leukemia: drug combo trial shows promise
Disease control CompletedThis early-stage trial tested a combination of two chemotherapy drugs (CPX-351) and a targeted antibody (GO) in children whose acute myeloid leukemia (AML) had returned or didn't respond to standard treatment. The goal was to find the safest dose and see if the combo could help c…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:46 UTC
-
Experimental combo targets tough leukemias
Disease control CompletedThis early-phase study tested a combination of two drugs—veliparib and temozolomide—in 66 adults with acute leukemias that had come back or not responded to standard treatment. The goal was to find the safest dose and see how well the combination worked. Veliparib blocks a repair…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Donor immune cells show promise for tough blood cancers
Disease control CompletedThis study tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) when standard drugs stop working. Nineteen adults received a special type of donor immune cell infusion designed to fight the cancer without causing long-ter…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo shows promise for Hard-to-Treat leukemia
Disease control CompletedThis study tested a new combination of drugs for people with a hard-to-treat type of leukemia called secondary AML. The goal was to find the best dose and see if the combo could help control the cancer. 37 adults took part in this early-phase trial.
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New liposome chemo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new form of chemotherapy called CPX-351 in 56 adults with a fast-growing blood cancer (acute myeloid leukemia) who were unlikely to respond to standard treatment. The drug combines two older chemo drugs inside a tiny fat bubble to help them work better togethe…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:22 UTC